ReviewArchives of microbiology2026
Advances in single-cell surface engineering: nano-coating and core-shell strategies for probiotics delivery in inflammatory bowel disease.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with a complex pathogenesis involving oxidative stress, intestinal barrier damage, gut microbiota dysbiosis, and immune imbalance. Conventional therapies merely alleviate symptoms but fail to achieve a radical cure, and long-term use is associated with adverse reaction and drug resistance. Probiotics represent a potential therapeutic strategy for IBD by regulating gut microecology, repairing the intestinal barrier, and modulating mucosal immunity, yet their clinical efficacy is severely limited by poor gastrointestinal tolerance, low viability, and inadequate colonization after oral administration. Inspired by bacterial self-protection mechanism, this review highlights innovative biomedical material-based probiotics delivery strategies for IBD, including microencapsulation, single-cell encapsulation, disease-targeted modification, and nanozyme integration. These engineered delivery systems innovatively endow probiotics with acid/bile salt resistance, site-specific targeting to inflamed intestinal mucosa, and reactive oxygen species scavenging capacity, while synergistically optimizing the pathological microenvironment of IBD to enhance probiotics colonization and functional activity. We further emphasize the clinical translation potential of these intelligent delivery platform, and discuss the key design principles for improving their biocompatibility, targeting efficiency, and scalability. This review aims to provide theoretical reference and experimental support for the development of intelligent, efficient probiotics delivery system with clinical translation potential, which may help address the unmet therapeutic needs of IBD and act as a novel adjunctive therapy for clinical practice in the future.
Indexed as
Identifiers
42029907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.